StockUS listing USMSLENASDAQHealthcareCapital Destroyer

Satellos Bioscience Inc. Common Stock(MSLE) Stock Analysis | Healthcare

USD --+0.00%
Reward36Moderate
Risk43Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 140.56M
Reward Ratingⓘ36 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ43 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on MSLE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Satellos Bioscience Inc. Common Stock?

, a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia.

AI Brief Pro

The brief on Satellos Bioscience Inc. Common Stock

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Satellos Bioscience Inc. Common Stock?

, a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 140.56M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (36)
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap140.56M
Beta1.189
Insider Activity
12M windowNo data
No insider activity data available for this ticker.